What Has Been the Growth of the Prostate Health Market So Far?
The prostate health market has seen considerable growth due to a variety of factors.
• Over the last few years, the prostate health market has experienced significant expansion. The market size, valued at $34.07 billion in 2024, is predicted to reach $37.34 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.6%.
The noticeable growth during this historical period can be traced back to factors such as the aging population, increased PSA screening, the proliferation of awareness campaigns, the progress in hormone therapy, and growing incidence rates.
How Will the Prostate Health Market?
The prostate health market is expected to maintain its strong growth trajectory in upcoming years.
• We can expect substantial expansion in the prostate health market in the upcoming years. By 2029, it's projected to flourish to $53.25 billion, with a compound annual growth rate (CAGR) of 9.3%.
The surge during the projected period is linked to the broader acceptance of precision medicine, an increase in ai-driven diagnostics, advancement of targeted radiotherapies, amplified calls for minimally invasive procedures, and enhanced genetic profiling for risk evaluation. Noteworthy trends for the forecasted timeframe include the application of AI in risk evaluation, progress in liquid biopsy technologies, the development of next-generation radiotheranostics, innovations in immunotherapy, and real-time biomarker surveillance.
Which Factors Are Boosting Growth In The Prostate Health Market?
The escalating cases of prostate cancer are anticipated to stimulate the expansion of the prostate health market. This cancer type transpires with unregulated cell growth in the prostate gland, typically presenting as adenocarcinomas, the prevalent form in males. The surge in prostate cancer incidence is chiefly attributed to the growing elderly population, intensified cancer screening practices, and lifestyle elements such as obesity and physical dormancy. The role of prostate health is vital for disease prevention, early diagnosis, and handling of prostate cancer. For instance, the American Cancer Society (ACS), a US-based non-profit organization, reported in January 2023 that approximately 288,300 new prostate cancer cases were projected to be registered in the U.S. in 2023, with an approximate 34,700 deaths resulting from the ailment. Hence, the escalating number of prostate cancer cases will serve as a catalyst for the growth of the prostate health market.
What Key Areas Define The Segmentation Of The Global Prostate Health Market?
The prostate health market covered in this report is segmented –
1) By Disease Indication: Prostate Cancer, Benign Prostate Hyperplasia, Prostatitis
2) By Treatment: Hormonal Therapy, Chemotherapy, Surgical Treatments, Other Treatments
3) By Distribution Channel: E-Commerce Stores, Pharmacies, Other Distribution Channels
Subsegments:
1) By Prostate Cancer: Localized Prostate Cancer, Metastatic Prostate Cancer
2) By Benign Prostate Hyperplasia: Mild BPH, Moderate BPH, Severe BPH
3) By Prostatitis: Acute Bacterial Prostatitis, Chronic Bacterial Prostatitis, Chronic Prostatitis (Non-Bacterial)
Pre-Book The Prostate Health Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Prostate Health Market?
Leading businesses in the prostate health market are leveraging technological developments like AI-powered risk metrics to build a competitive advantage. This kind of risk evaluation uses AI algorithms to examine data and forecast potential dangers, aiding in decision-making and enhancing outcomes. For instance, Nanostics Inc., a clinical-stage biotech firm based in Canada, along with Protean BioDiagnostics, a US-based biotech company, collaborated in September 2024 to launch CDX Prostate, a diagnostic device intended for men who are prone to severe prostate cancer. This device leverages biological data, clinical data, and AI-informed learning models to yield a risk score for aggressive prostate cancer. Advanced machine learning algorithms are used to evaluate various biological and clinical data in CDX Prostate, offering a more accurate risk score for severe prostate cancer than conventional methods. The test enables healthcare professionals and patients to make knowledgeable decisions on whether to go for a biopsy following a high prostate-specific antigen (PSA) test result or an unusual digital rectal exam (DRE).
Who Are the Key Players In The Prostate Health Market?
Major companies operating in the prostate health market are:
• Pfizer Inc.
• Johnson & Johnson
• Siemens Healthineers AG
• Bayer AG
• Sanofi SA
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• Takeda Pharmaceutical Co Ltd
• Astellas Pharma Inc
• Genentech Inc.
• Teleflex Inc.
• Elekta AB
• Myriad Genetics Inc.
• Freenome
• Theragenics Corporation
• CureVac BV
• ArsenalBio
• Roivant Sciences
• Artera Inc.
• Veru Inc.
• HistoSonics Inc.
• Immunic Inc.
• Ezra
• Francis Medical
• CorTechs Labs
• Lucida Medical
• Serimmune Inc.
• Alessa Therapeutics.
What Is The Most Dominant Region In The Prostate Health Market?
North America was the largest region in the prostate health market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
